One study comparedde novoand recall immune responses between patients with chronic lymphocytic leukemia (CLL) who were treated with Bruton’s tyrosine kinase (IBTK) inhibitors and patients who were never treated with these inhibitors. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.